Denali Therapeutics (DNLI) Stock Forecast & Price Target

Compare

820 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DNLI Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Denali

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DNLI Stock 12 Month Forecast

Average Price Target

$32.36

▲(90.91% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Denali Therapeutics in the last 3 months. The average price target is $32.36 with a high forecast of $40.00 and a low forecast of $25.00. The average price target represents a 90.91% change from the last price of $16.95.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","26":"$26","41":"$41","18.5":"$18.5","33.5":"$33.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,18.5,26,33.5,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.51,18.31692307692308,20.123846153846156,21.930769230769233,23.73769230769231,25.544615384615383,27.35153846153846,29.158461538461538,30.965384615384615,32.77230769230769,34.57923076923077,36.386153846153846,38.19307692307692,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.51,17.72923076923077,18.94846153846154,20.16769230769231,21.38692307692308,22.60615384615385,23.825384615384614,25.044615384615383,26.263846153846153,27.483076923076922,28.70230769230769,29.92153846153846,31.14076923076923,{"y":32.36,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.51,17.163076923076925,17.81615384615385,18.46923076923077,19.122307692307693,19.775384615384617,20.42846153846154,21.081538461538464,21.734615384615385,22.38769230769231,23.040769230769232,23.693846153846152,24.346923076923076,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.38,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.56,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.06,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.96,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.91,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.16,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.51,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$40.00

Average Price Target$32.36

Lowest Price Target$25.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sean Laaman

Morgan Stanley

$32→$40

Buy

135.99%

Upside

Reiterated

01/08/26

Denali Therapeutics price target raised to $40 from $32 at Morgan StanleyDenali Therapeutics price target raised to $40 from $32 at Morgan Stanley

Myles Minter

William Blair

Buy

―

Reiterated

01/07/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Sandoz Group Ltd (Other OTC: SDZXF) and Denali Therapeutics (NASDAQ: DNLI)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$40

Buy

135.99%

Upside

Reiterated

01/07/26

Jefferies Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

Michael Yee

UBS

$25

Buy

47.49%

Upside

Initiated

01/06/26

Denali Therapeutics assumed with a Buy at UBSDenali Therapeutics assumed with a Buy at UBS

Laura Chico

Wedbush

$31→$30

Buy

76.99%

Upside

Reiterated

12/11/25

Denali Therapeutics (DNLI) Gets a Buy from Wedbush

Paul Matteis

Stifel Nicolaus

$37

Buy

118.29%

Upside

Reiterated

12/05/25

Denali Therapeutics (DNLI) Gets a Buy from Stifel Nicolaus

Thomas Shrader

BTIG

$32

Buy

88.79%

Upside

Reiterated

12/04/25

Denali Therapeutics: Promising Future with Strategic Agreements and Innovative Programs

Tazeen Ahmad

Bank of America Securities

$26→$29

Buy

71.09%

Upside

Reiterated

12/04/25

Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Cytokinetics (NASDAQ: CYTK) and Denali Therapeutics (NASDAQ: DNLI)

Andrew Fein

H.C. Wainwright

$32

Buy

88.79%

Upside

Reiterated

12/03/25

H.C. Wainwright Keeps Their Buy Rating on Denali Therapeutics (DNLI)

Mayank Mamtani

B. Riley Securities

$30

Buy

76.99%

Upside

Reiterated

12/01/25

B. Riley Securities Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

Jay Olson

Oppenheimer

$35

Buy

106.49%

Upside

Reiterated

11/10/25

Oppenheimer Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

Joseph Thome

TD Cowen

Buy

―

Reiterated

11/06/25

Denali Therapeutics: Promising Pipeline and Strategic Progress Justify Buy Rating

Jessica Fye

J.P. Morgan

$26

Buy

53.39%

Upside

Reiterated

11/03/25

Denali Therapeutics (DNLI) Gets a Buy from J.P. Morgan

Joshua Schimmer

Cantor Fitzgerald

Buy

―

Reiterated

09/08/25

Denali Therapeutics (DNLI) Receives a Buy from Cantor Fitzgerald

Marc Goodman

Leerink Partners

$40

Buy

135.99%

Upside

Reiterated

08/13/25

Denali Therapeutics: Promising Developments and Financial Stability Drive Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sean Laaman

Morgan Stanley

$32→$40

Buy

135.99%

Upside

Reiterated

01/08/26

Denali Therapeutics price target raised to $40 from $32 at Morgan StanleyDenali Therapeutics price target raised to $40 from $32 at Morgan Stanley

Myles Minter

William Blair

Buy

―

Reiterated

01/07/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Sandoz Group Ltd (Other OTC: SDZXF) and Denali Therapeutics (NASDAQ: DNLI)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$40

Buy

135.99%

Upside

Reiterated

01/07/26

Jefferies Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

Michael Yee

UBS

$25

Buy

47.49%

Upside

Initiated

01/06/26

Denali Therapeutics assumed with a Buy at UBSDenali Therapeutics assumed with a Buy at UBS

Laura Chico

Wedbush

$31→$30

Buy

76.99%

Upside

Reiterated

12/11/25

Denali Therapeutics (DNLI) Gets a Buy from Wedbush

Paul Matteis

Stifel Nicolaus

$37

Buy

118.29%

Upside

Reiterated

12/05/25

Denali Therapeutics (DNLI) Gets a Buy from Stifel Nicolaus

Thomas Shrader

BTIG

$32

Buy

88.79%

Upside

Reiterated

12/04/25

Denali Therapeutics: Promising Future with Strategic Agreements and Innovative Programs

Tazeen Ahmad

Bank of America Securities

$26→$29

Buy

71.09%

Upside

Reiterated

12/04/25

Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Cytokinetics (NASDAQ: CYTK) and Denali Therapeutics (NASDAQ: DNLI)

Andrew Fein

H.C. Wainwright

$32

Buy

88.79%

Upside

Reiterated

12/03/25

H.C. Wainwright Keeps Their Buy Rating on Denali Therapeutics (DNLI)

Mayank Mamtani

B. Riley Securities

$30

Buy

76.99%

Upside

Reiterated

12/01/25

B. Riley Securities Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

Jay Olson

Oppenheimer

$35

Buy

106.49%

Upside

Reiterated

11/10/25

Oppenheimer Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

Joseph Thome

TD Cowen

Buy

―

Reiterated

11/06/25

Denali Therapeutics: Promising Pipeline and Strategic Progress Justify Buy Rating

Jessica Fye

J.P. Morgan

$26

Buy

53.39%

Upside

Reiterated

11/03/25

Denali Therapeutics (DNLI) Gets a Buy from J.P. Morgan

Joshua Schimmer

Cantor Fitzgerald

Buy

―

Reiterated

09/08/25

Denali Therapeutics (DNLI) Receives a Buy from Cantor Fitzgerald

Marc Goodman

Leerink Partners

$40

Buy

135.99%

Upside

Reiterated

08/13/25

Denali Therapeutics: Promising Developments and Financial Stability Drive Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Denali Therapeutics

1 Month

xxx

Success Rate

12/15 ratings generated profit

Average Return

+9.57%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +9.57% per trade.

3 Months

xxx

Success Rate

10/18 ratings generated profit

Average Return

+13.12%

reiterated a xxx

rating 30 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +13.12% per trade.

1 Year

Laura ChicoWedbush

Success Rate

9/18 ratings generated profit

Average Return

+14.03%

reiterated a buy rating 30 days ago

Copying Laura Chico's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +14.03% per trade.

2 Years

xxx

Success Rate

8/20 ratings generated profit

Average Return

-3.62%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -3.62% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DNLI Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DNLI has received 21 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. DNLI average Analyst price target in the past 3 months is 32.36.

Each month's total comprises the sum of three months' worth of ratings.

DNLI Financial Forecast

DNLI Earnings Forecast

Next quarter’s earnings estimate for DNLI is -$0.75 with a range of -$0.93 to -$0.62. The previous quarter’s EPS was -$0.74. DNLI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year DNLI has Performed in-line its overall industry.

DNLI Sales Forecast

Next quarter’s sales forecast for DNLI is $3.08M with a range of $0.00 to $25.00M. The previous quarter’s sales results were $0.00. DNLI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year DNLI has Performed in-line its overall industry.

DNLI Stock Forecast FAQ

What is DNLI’s average 12-month price target, according to analysts?

Based on analyst ratings, Denali Therapeutics’s 12-month average price target is 32.36.

What is DNLI’s upside potential, based on the analysts’ average price target?

Denali Therapeutics has 90.91% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DNLI a Buy, Sell or Hold?

Denali Therapeutics has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Denali Therapeutics’s price target?

The average price target for Denali Therapeutics is 32.36. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $25.00. The average price target represents 90.91% Increase from the current price of $16.95.

What do analysts say about Denali Therapeutics?

Denali Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of DNLI?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Denali Therapeutics (DNLI) Stock Forecast & Price Target

DNLI Analyst Ratings

DNLI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Denali Therapeutics

DNLI Analyst Recommendation Trends

DNLI Financial Forecast

DNLI Earnings Forecast

DNLI Sales Forecast

DNLI Stock Forecast FAQ

Detailed List of Analyst Forecasts